This company listing is no longer active
MorphoSys Valuation
Is MOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MOR?
Key metric: As MOR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MOR's PS Ratio? | |
|---|---|
| PS Ratio | 10.5x |
| Sales | €241.47m |
| Market Cap | €2.53b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.1x |
| Enterprise Value/EBITDA | -9.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MOR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.7x | ||
THQM Tchaikapharma High Quality Medicines AD | 32.4x | n/a | лв1.6b |
000403 Pacific Shuanglin Bio-pharmacy | 5.5x | 15.0% | CN¥15.5b |
ACAD ACADIA Pharmaceuticals | 2.9x | 9.1% | US$2.8b |
FOLD Amicus Therapeutics | 6x | 19.5% | US$2.9b |
MOR MorphoSys | 10.5x | 26.2% | €2.5b |
Price-To-Sales vs Peers: MOR is good value based on its Price-To-Sales Ratio (10.5x) compared to the peer average (10.7x).
Price to Sales Ratio vs Industry
How does MOR's PS Ratio compare vs other companies in the European Biotechs Industry?
| 39 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 39 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the European Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is MOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MOR's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €61.00 0% | 19.9% | €68.00 | €40.00 | n/a | 4 |
| Nov ’25 | n/a | €61.00 0% | 19.9% | €68.00 | €40.00 | n/a | 4 |
| Oct ’25 | n/a | €61.00 0% | 19.9% | €68.00 | €40.00 | n/a | 4 |
| Sep ’25 | n/a | €61.00 0% | 19.9% | €68.00 | €40.00 | n/a | 4 |
| Aug ’25 | €67.85 | €58.71 -13.5% | 25.3% | €68.00 | €31.00 | n/a | 7 |
| Jul ’25 | €67.70 | €58.71 -13.3% | 25.3% | €68.00 | €31.00 | n/a | 7 |
| Jun ’25 | €68.03 | €58.71 -13.7% | 25.3% | €68.00 | €31.00 | n/a | 7 |
| May ’25 | €66.03 | €58.71 -11.1% | 25.3% | €68.00 | €31.00 | n/a | 7 |
| Apr ’25 | €67.21 | €58.71 -12.6% | 25.3% | €68.00 | €31.00 | n/a | 7 |
| Mar ’25 | €65.24 | €50.38 -22.8% | 36.4% | €68.00 | €22.00 | n/a | 8 |
| Feb ’25 | €40.41 | €31.35 -22.4% | 33.5% | €47.00 | €15.00 | n/a | 10 |
| Jan ’25 | €34.10 | €31.00 -9.1% | 33.6% | €47.00 | €15.00 | n/a | 10 |
| Dec ’24 | €23.15 | €31.13 +34.5% | 33.3% | €47.00 | €15.00 | n/a | 8 |
| Nov ’24 | €30.80 | €34.33 +11.5% | 17.8% | €45.00 | €25.00 | n/a | 9 |
| Oct ’24 | €26.10 | €31.61 +21.1% | 29.1% | €45.00 | €13.50 | n/a | 9 |
| Sep ’24 | €28.06 | €27.94 -0.4% | 38.9% | €45.00 | €12.50 | n/a | 8 |
| Aug ’24 | €27.13 | €28.19 +3.9% | 40.0% | €47.00 | €12.50 | €67.85 | 8 |
| Jul ’24 | €27.45 | €25.56 -6.9% | 50.9% | €47.00 | €12.50 | €67.70 | 8 |
| Jun ’24 | €23.93 | €23.06 -3.6% | 59.3% | €47.00 | €12.00 | €68.03 | 8 |
| May ’24 | €18.89 | €18.31 -3.1% | 58.8% | €42.00 | €11.00 | €66.03 | 8 |
| Apr ’24 | €14.78 | €18.31 +23.9% | 58.8% | €42.00 | €11.00 | €67.21 | 8 |
| Mar ’24 | €17.14 | €18.25 +6.5% | 59.2% | €42.00 | €11.00 | €65.24 | 8 |
| Feb ’24 | €18.64 | €23.44 +25.8% | 76.2% | €65.00 | €11.00 | €40.41 | 9 |
| Jan ’24 | €13.18 | €25.06 +90.1% | 67.8% | €65.00 | €12.00 | €34.10 | 9 |
| Dec ’23 | €15.66 | €29.11 +85.9% | 60.9% | €65.00 | €13.00 | €23.15 | 9 |
| Nov ’23 | €19.93 | €35.61 +78.7% | 39.6% | €65.00 | €18.00 | €30.80 | 9 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Evotec
€1.7b
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
EVT
€8.82
7D
0%
1Y
n/a
Novavax
US$1.5b
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
NVV1
US$8.56
7D
27.8%
1Y
55.9%
Tilray Brands
US$1.5b
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
2HQ
US$1.58
7D
0%
1Y
n/a